Copycats hurt Amgen in 2019. Can Otezla, new launches ease the pain?

30th January 2020 Uncategorised 0

Amgen finished 2019 with another dip in sales thanks to generic and biosimilar challenges to some of its top meds, including blockbuster Neulasta. But for 2020, the drugmaker sees better days ahead thanks to new launches, the recently acquired Otezla and its own biosimilar franchise.

More: Copycats hurt Amgen in 2019. Can Otezla, new launches ease the pain?
Source: fierce